Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
miR-17~92 targeting RNA aptamer
- Development stage
- Preclinical
- Modality
- RNA Aptamers → RNA Therapeutics → Nucleic Acid Therapeutics, DNA Aptamers → DNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
miR-17~92 targeting RNA aptamer is an RNA aptamer designed to specifically target the primary transcript of the oncogenic microRNA-17~92 (pri-miR-17~92) cluster. This cluster, also known as oncomiR-1, is frequently overexpressed in various human cancers and plays a crucial role in regulating cell proliferation, apoptosis, and differentiation. The aptamer functions by binding to the pri-miR-17~92 transcript, which interferes with its processing and maturation into individual microRNAs such as miR-17, miR-18a, miR-19b, and miR-20a. By inhibiting the biogenesis of these oncogenic microRNAs, the aptamer aims to suppress cancer cell growth, induce cell cycle arrest, and promote apoptosis, thereby offering a therapeutic strategy for cancers driven by the miR-17~92 cluster.
- Other names
- pri-miRNA-17~92 aptamerpri-apt
Beyond the preview
Go deeper on miR-17~92 targeting RNA aptamer.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on miR-17~92 targeting RNA aptamer.